Patents by Inventor Anthony S. Prokopowicz, III
Anthony S. Prokopowicz, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8450317Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 to R5, A, B, D and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: GrantFiled: April 27, 2010Date of Patent: May 28, 2013Assignee: Boehringer Ingelheim International GmbHInventors: Jennifer A. Kowalski, Daniel Richard Marshall, Anthony S. Prokopowicz, III, Sabine Schlyer, Robert Sibley, Ronald John Sorcek, Di Wu, Frank Wu, Erick Richard Roush Young
-
Patent number: 8318723Abstract: The invention provides compounds according to formula (I) their use and methods for preparation wherein A, X, Y, R1, R2 and R3 are defined herein. The compounds of the invention inhibit specific serine/threonine kinases involved in inflammatory processes and aberrant cell proliferation, and are thus useful for treating associated diseases and pathological conditions such as Pim kinase-mediated diseases and pathological conditions involving inflammation, including Chron's disease, inflammatory bowel disease, rheumatoid arthritis, and chronic inflammatory disease, or aberrant cell proliferation including various cancers.Type: GrantFiled: August 15, 2007Date of Patent: November 27, 2012Assignee: Boehringer Ingelheim International GmbHInventors: Wang Mao, Tina Marie Morwick, Anthony S. Prokopowicz, III
-
Publication number: 20100280028Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 to R5, A, B, D and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: ApplicationFiled: April 27, 2010Publication date: November 4, 2010Applicant: Boehringer Ingelheim International GmbHInventors: Jennifer A. KOWALSKI, Daniel Richard MARSHALL, Anthony S. PROKOPOWICZ, III, Sabine SCHLYER, Robert SIBLEY, Ronald John SORCEK, Di WU, Frank WU, Erick Richard Roush YOUNG
-
Publication number: 20100210627Abstract: The invention provides compounds according to formula (I) their use and methods for preparation wherein A, X, Y, R1, R2 and R3 are defined herein. The compounds of the invention inhibit specific serine/threonine kinases involved in inflammatory processes and aberrant cell proliferation, and are thus useful for treating associated diseases and pathological conditions such as Pim kinase-mediated diseases and pathological conditions involving inflammation, including Chron's disease, inflammatory bowel disease, rheumatoid arthritis, and chronic inflammatory disease, or aberrant cell proliferation including various cancers.Type: ApplicationFiled: August 15, 2007Publication date: August 19, 2010Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Wang Mao, Tina Marie Morwick, Anthony S. Prokopowicz, III
-
Patent number: 7588899Abstract: The invention provides methods relating to a screening assay format that can be applied to broad members of the protein kinase gene family. The assay uses a series of labeled, active site probes described herein that can be displaced by an inhibitor agent. The Kd for the inhibitor compound is derived based on the Kd of the probe for the kinase and the dose response of the inhibitor agent. The invention also provides active site probes suitable for use with the screening method.Type: GrantFiled: July 25, 2006Date of Patent: September 15, 2009Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Anthony S. Prokopowicz, III, Martha Priscilla Brown, Jessi Marie Wildeson, Scott Jakes, Mark E. Labadia
-
Patent number: 7550473Abstract: Disclosed are novel compounds of formula (I): wherein R1, R2 and R3 are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: GrantFiled: September 3, 2004Date of Patent: June 23, 2009Assignees: Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Mario G. Cardozo, Derek Cogan, Charles Lawrence Cywin, George Dahmann, Darren DiSalvo, John David Ginn, Anthony S. Prokopowicz, III, Denice M. Spero, Erick Richard Roush Young
-
Patent number: 7125996Abstract: The invention provides methods relating to a novel screening assay format that can be applied to broad members of the protein kinase gene family. The assay uses a series of labeled, active site probes described herein that can be displaced by an inhibitor agent. The Kd for the inhibitor compound is derived based on the Kd of the probe for the kinase and the dose response of the inhibitor agent. The invention also provides active site probes suitable for use with the screening method.Type: GrantFiled: September 30, 2004Date of Patent: October 24, 2006Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Anthony S. Prokopowicz, III, Martha Priscilla Brown, Jessi Marie Wildeson, Scott Jakes, Mark E. Labadia
-
Patent number: 6844435Abstract: Disclosed are novel compounds of formula (I): wherein Ar1, X, Y, P, Q and Het are defined herein, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases resulting from inappropriate cell proliferation, which include autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer, as well as conditions resulting from cerebral ischemia, such as stroke. Also disclosed are pharmaceutical compositions comprising these compounds, processes for preparing these compounds and novel intermediate compounds useful in these processes.Type: GrantFiled: October 15, 2002Date of Patent: January 18, 2005Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Roger John Snow, Donghong A. Gao, Daniel R. Goldberg, Abdelhakim Hammach, Daniel Kuzmich, Tina Marie Morwick, Neil Moss, Anthony S. Prokopowicz, III, Robert D. Selliah, Hidenori Takahashi
-
Patent number: 6770639Abstract: Disclosed are novel compounds of formula (I): wherein Ar1, Ra, R4, R5, X and Y are defined below, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases associated with such kinases, for example, diseases resulting from inappropriate cell proliferation, which include autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer, as well as conditions resulting from cerebral ischemia, such as stroke. Also disclosed are processes for preparing these compounds, novel intermediates useful in these processes and compositions comprising compounds of the formula (I).Type: GrantFiled: November 12, 2002Date of Patent: August 3, 2004Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Roger John Snow, Mario Cardozo, Daniel Goldberg, Abdelhakim Hammach, Tina Morwick, Neil Moss, Usha R. Patel, Anthony S. Prokopowicz, III, Hidenori Takahashi, Matt Aaron Tschantz, Xiao-Jun Wang
-
Patent number: 6506769Abstract: Disclosed are novel compounds of formula (I): wherein Ar1, Ra, R4, R5, X and Y are defined below, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases associated with such kinases, for example, diseases resulting from inappropriate cell proliferation, which include autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer, as well as conditions resulting from cerebral ischemia, such as stroke. Also disclosed are processes for preparing these compounds, novel intermediates useful in these processes and compositions comprising compounds of the formula (I).Type: GrantFiled: August 2, 2001Date of Patent: January 14, 2003Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Roger John Snow, Mario Cardozo, Daniel Goldberg, Abdelhakim Hammach, Tina Morwick, Neil Moss, Usha R. Patel, Anthony S. Prokopowicz, III, Hidenori Takahashi, Matt Aaron Tschantz, Xiao-Jun Wang
-
Patent number: 6489328Abstract: Disclosed are novel compounds of formula (I): wherein Ar1, X, Y, P, Q and Het are defined herein, which are useful as inhibitors of certain protein tyrosine kinases and are thus useful for treating diseases resulting from inappropriate cell proliferation, which include autoimmune diseases, chronic inflammatory diseases, allergic diseases, transplant rejection and cancer, as well as conditions resulting from cerebral ischemia, such as stroke. Also disclosed are pharmaceutical compositions comprising these compounds, processes for preparing these compounds and novel intermediate compounds useful in these processes.Type: GrantFiled: August 2, 2001Date of Patent: December 3, 2002Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Roger John Snow, Donghong A. Gao, Daniel R. Goldberg, Abdelhakim Hammach, Daniel Kuzmich, Tina Marie Morwick, Neil Moss, Anthony S. Prokopowicz, III, Robert D. Selliah, Hidenori Takahashi